The Immun4Cure institute aims to break with conventional therapeutic programmes by offering new cellular and biological therapeutic tools to completely restore immune homeostasis in autoimmune diseases and change the course of care and prognosis.
The Immun4Cure University Hospital Institute (IHU) is an innovative project that will change the course, management and treatment of autoimmune diseases. This Institute was built on the momentum of Montpellier researchers with the ambition of becoming the European centre for research and development in immunotherapy for autoimmune diseases.
Since 2014, the Institute of Regenerative Medicine and Biotherapies (IRMB) has been dedicated to understanding the mechanisms of regeneration and inflammatory processes, combining fundamental and clinical research. This joint institute – University of Montpellier, Inserm and Montpellier University Hospital – led by Prof. Jorgensen, aims to identify innovative concepts and treatments that can then be validated in the laboratory and offered to patients through clinical trials.
It brings together nearly 160 researchers, engineers and doctors specialising in the development of innovative therapies – stem cells and tissue regeneration, targeted immunotherapies – to envisage future treatments for all chronic diseases. The IRMB is also a training ground for aspiring researchers and doctors wishing to pursue a dual degree. More than a dozen high-level technical and technological platforms complete the picture.
Since 2017, thanks to the State-Metropolis Pact, the IRMB has also been unique in serving as a business incubator hosting 10 start-ups. They work closely with Professor Jorgensen’s teams. He also coordinates several European programmes for the study and evaluation of diseases such as osteoarthritis and rheumatoid arthritis (notably the ADIPOA and RESPINE programmes). Building on this solid foundation, Professor Jorgensen, with an expanded team and in agreement with Montpellier University Hospital, Inserm and the University of Montpellier, responded in 2022 to the IHU3 call for projects with a proposal for an institute integrating care, the development of cell biotherapy and training in the use of these new strategies.
The Immu4Cure project, led by Montpellier University Hospital, Inserm and the University of Montpellier, was awarded IHU status in May 2023 as part of the France 2030 plan.
An initiative of excellence, the IHU brings together expertise in systemic autoimmune diseases and is fully in line with the MedVallée dynamic, capitalising on its strengths and reinforcing communities already recognised by the I-SITE label.
The collective mobilisation of the City of Montpellier, Montpellier Méditerranée Métropole, the Occitanie Region and the hospital and scientific community around this project has secured €20 million in funding over 10 years, confirming Montpellier’s position as a global centre of excellence in global health.
The IHU draws on the expertise of :
to keep you informed
Form and map
Make a donation...
